182287-63-4

Usage

Uses

Used in Pharmaceutical Industry:
4-(Bromomethyl)-3-iodobenzonitrile is used as a synthetic intermediate for the production of pharmaceuticals, facilitating the creation of a range of medicinal compounds that address diverse health conditions.
Used in Agrochemical Industry:
In the agrochemical sector, 4-(Bromomethyl)-3-iodobenzonitrile serves as a key intermediate, playing a crucial role in the synthesis of various agrochemicals that are essential for crop protection and enhancement of agricultural productivity.
Used in Organic Synthesis:
4-(Bromomethyl)-3-iodobenzonitrile is utilized as a precursor in organic synthesis for preparing a variety of functionalized aromatic compounds, which are vital in the development of new materials and chemical entities with specific applications.
Safety and Environmental Considerations:
It is imperative to handle 4-(Bromomethyl)-3-iodobenzonitrile with care due to its classification as a hazardous substance. Exposure may result in skin and eye irritation, as well as respiratory issues if inhaled. Moreover, proper handling and disposal are necessary to prevent harm to aquatic life and the environment.

Upstream product

• 42872-79-7 3-iodo-4-methylbenzonitrile 

Downstream Products

• 450844-38-9 5-[(4-cyano-2-iodobenzyloxy)-(4-cyanophenyl)methyl]-1-methyl-1H-imidazole 
• 628686-14-6 4-[(4-Cyano-phenyl)-(3-methyl-3H-imidazol-4-yl)-methoxymethyl]-3-(4-nitro-phenylethynyl)-benzonitrile 
• 628686-08-8 4-[(4-Cyano-phenyl)-(3-methyl-3H-imidazol-4-yl)-methoxymethyl]-3-pyridin-2-ylethynyl-benzonitrile 
• 628686-05-5 4-[(4-Cyano-phenyl)-(3-methyl-3H-imidazol-4-yl)-methoxymethyl]-3-(3,3-dimethyl-but-1-ynyl)-benzonitrile 

Relevant academic research and scientific papers

ALDOSTERONE SYNTHASE INHIBITOR

PROBLEM TO BE SOLVED: To provide a compound having aldosterone synthase inhibition effect useful for treatment of primary aldosteronism causing hypertension or hypokalemia by overproduction of aldosterone, and a pharmaceuticals containing the compound. SOLUTION: There are provided an imidazole compound including 4-[5-(2-fluoroethyl)-1H-imidazole-1-ylmethyl]-3-iodobenzonitrile, 1-(3-bromo-4-cyanobenzyl)-1H-imidazole-5-carboxylic acid methyl, 1-(2-iodo-4-nitrobenzyl)-1H-imidazole-5-carboxylic acid methyl, 1-(3,5-di-tert-butylphenyl)-1H-imidazole-5-carboxylic acid methyl, 1-(2H-chromene-2-on-6-ylmethyl)-1H-imidazole-5-carboxylic acid methyl and 1-(2H-chromene-2-on-6-ylmethyl)-5-iodo-1H-imidazole as examples, and pharmaceuticals containing the compound. COPYRIGHT: (C)2015,JPOandINPIT

RADIOACTIVE HALOGEN LABELED COMPOUNDS OR SALTS THEREOF, AND PHARMACEUTICALS CONTAINING THE SAME

PROBLEM TO BE SOLVED: To provide radioactive halogen labeled compounds which have high selectivity for CYP11B2 over CYP11B1 and accumulation selectivity in the adrenal gland compared to the surrounding organs. SOLUTION: The present invention provides radi

Synthesis and biological evaluation of 4-[(3-methyl-3H-imidazol-4-yl)-(2-phenylethynyl-benzyloxy)-methyl]-benzonitrile as novel farnesyltransferase inhibitor

Farnesyltransferase inhibitors (FTIs) have emerged as a novel class of anticancer agents. Analogues of the potent FTI, 4-[3-biphenyl-1-hydroxy-1-(3-methyl-3H-imidazol-4-yl)-prop-2-ynyl] -1-yl-benzonitrile, were synthesized and tested in vitro for their in